State Board of Administration of Florida Retirement System decreased its position in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 9.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 25,011 shares of the specialty pharmaceutical company’s stock after selling 2,751 shares during the quarter. State Board of Administration of Florida Retirement System owned about 0.07% of AMAG Pharmaceuticals worth $322,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also recently made changes to their positions in the stock. California Public Employees Retirement System increased its stake in shares of AMAG Pharmaceuticals by 0.8% during the 4th quarter. California Public Employees Retirement System now owns 86,987 shares of the specialty pharmaceutical company’s stock valued at $1,321,000 after acquiring an additional 690 shares during the last quarter. Texas Permanent School Fund increased its stake in shares of AMAG Pharmaceuticals by 4.2% during the 4th quarter. Texas Permanent School Fund now owns 22,600 shares of the specialty pharmaceutical company’s stock valued at $343,000 after acquiring an additional 909 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of AMAG Pharmaceuticals by 1.1% during the 1st quarter. Rhumbline Advisers now owns 103,866 shares of the specialty pharmaceutical company’s stock worth $1,338,000 after purchasing an additional 1,125 shares during the period. Strs Ohio grew its holdings in shares of AMAG Pharmaceuticals by 4.2% during the 4th quarter. Strs Ohio now owns 39,500 shares of the specialty pharmaceutical company’s stock worth $600,000 after purchasing an additional 1,600 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in shares of AMAG Pharmaceuticals by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 285,332 shares of the specialty pharmaceutical company’s stock worth $4,334,000 after purchasing an additional 1,613 shares during the period.
In related news, major shareholder Armistice Capital, Llc bought 259,016 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were purchased at an average cost of $8.59 per share, with a total value of $2,224,947.44. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William K. Heiden bought 10,000 shares of the company’s stock in a transaction on Thursday, May 9th. The stock was bought at an average cost of $10.70 per share, for a total transaction of $107,000.00. Following the completion of the transaction, the chief executive officer now directly owns 490,056 shares of the company’s stock, valued at $5,243,599.20. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 328,016 shares of company stock worth $2,904,577. Corporate insiders own 4.90% of the company’s stock.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($2.77). The firm had revenue of $75.80 million for the quarter, compared to analyst estimates of $90.13 million. AMAG Pharmaceuticals had a negative net margin of 30.90% and a negative return on equity of 26.33%. The business’s revenue was down 35.4% on a year-over-year basis. During the same period in the prior year, the company posted ($1.59) earnings per share. On average, analysts anticipate that AMAG Pharmaceuticals, Inc. will post -2.15 earnings per share for the current fiscal year.
A number of analysts have recently issued reports on AMAG shares. BidaskClub cut AMAG Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, March 7th. Cantor Fitzgerald restated a “hold” rating and issued a $14.00 price target (down previously from $17.00) on shares of AMAG Pharmaceuticals in a report on Thursday, March 14th. SunTrust Banks began coverage on AMAG Pharmaceuticals in a report on Tuesday, March 19th. They issued a “hold” rating for the company. Zacks Investment Research cut AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 20th. Finally, ValuEngine upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $16.92.
AMAG Pharmaceuticals Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Recommended Story: What are the economic characteristics of a bear market?
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.